Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial

被引：0

作者：

Shumack, Stephen ^{[1
]}

Blauvelt, Andrew ^{[2
]}

Iversen, Lars ^{[3
]}

McBride, Sandy ^{[4
]}

Gooderham, Melinda ^{[5
,6
]}

Staubach-Renz, Petra ^{[7
]}

Yamauchi, Paul ^{[8
,9
]}

Staelens, Fabienne ^{[10
]}

Vanvoorden, Veerle ^{[10
]}

White, Katy ^{[10
]}

Gisondi, Paolo ^{[11
]}

机构：

[1] St George Dermatol & Skin Canc Ctr, Kogarah, NSW, Australia

[2] Oregon Med Res Ctr, Portland, OR USA

[3] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark

[4] Royal Free London NHS Fdn Trust, London, England

[5] Queens Univ, SKiN Ctr Dermatol, Peterborough, ON, Canada

[6] Prob Med Res, Peterborough, ON, Canada

[7] Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, Mainz, Germany

[8] Dermatol Inst & Skin Care Ctr, Santa Monica, CA USA

[9] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA USA

[10] UCB Pharma, Brussels, Belgium

[11] Univ Hosp Verona, Verona, Italy

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：17 / 18

页数：2

共 50 条

[31] Bimekizumab efficacy and safety through 2 years in patients with moderate to severe plaque psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Penas, Pablo Fernandez
Gordon, Kenneth B.
Armstrong, April W.
Lebwohl, Mark
Blauvelt, Andrew
Paul, Carle
Wang, Maggie
Vanvoorden, Veerle
Madden, Cynthia
Gomez, Natalie Nunez
Deherder, Delphine
Thaci, Diamant
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 20 - 20
[32] Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
Blauvelt, Andrew
Armstrong, April W.
Langley, Richard G.
Gebauer, Kurt
Thaci, Diamant
Bagel, Jerry
Guenther, Lyn C.
Paul, Carle
Randazzo, Bruce
Flavin, Susan
Hsu, Ming-Chun
You, Yin
Reich, Kristian
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2317 - 2324
[33] Secukinumab efficacy in patients with moderate to severe plaque psoriasis and psoriatic arthritis: A phase II, double-blind, randomized trial
Gottlieb, Alice B.
Guettner, Achim
Papavassilis, Charis
Helliwell, Philip
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB212 - AB212
[34] Secukinumab efficacy and safety in subjects with moderate to severe plaque psoriasis: Results from the Judging the efficacy of secUkinumab in patients with psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE)
Blauvelt, Andrew
Gottlieb, Alice
Prinz, Jorg
Pathan, Rashidkhan
Cooper, Simon
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB185 - AB185
[35] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY):a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (vol 397, pg 475, 2021)
Gordon, K. B.
Foley, P.
Krueger, J. G.
LANCET, 2021, 397 (10280): : 1182 - 1182
[36] Bimekizumab vs adalimumab in plaque psoriasis: Higher efficacy translates into improvements in quality of life in the BE SURE multicenter, randomized, double-blinded phase 3 trial
Blauvelt, Andrew
Thaci, Diamant
Papp, Kim A.
Merola, Joseph F.
Cullen, Eva
Vanvoorden, Veerle
Ciaravino, Valerie
Peterson, Luke
Gordon, Kenneth
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB146 - AB146
[37] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
Strober, Bruce
Thaci, Diamant
Sofen, Howard
Kircik, Leon
Gordon, Kenneth B.
Foley, Peter
Rich, Phoebe
Paul, Carle
Bagel, Jerry
Colston, Elizabeth
Throup, John
Kundu, Sudeep
Sekaran, Chitra
Linaberry, Misti
Banerjee, Subhashis
Papp, Kim A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : 40 - 51
[38] Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Reich, Kristian
Papp, Kim A.
Blauvelt, Andrew
Langley, Richard G.
Armstrong, April
Warren, Richard B.
Gordon, Kenneth B.
Merola, Joseph F.
Okubo, Yukari
Madden, Cynthia
Wang, Maggie
Cioffi, Christopher
Vanvoorden, Veerle
Lebwohl, Mark
LANCET, 2021, 397 (10273): : 487 - 498
[39] Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study
Wright, Grace
Nash, Peter
Coates, Laura
Gratacos, Jordi
Behrens, Frank
Ding, Kevin
Bao, Weibin
Pricop, Luminita
Gaillez, Corine
McInnes, Iain
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[40] Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial
Bagel, Jerry
Nia, John
Hashim, Peter W.
Patekar, Manmath
Hugot, Sophie
Sheng, Kuan
Xia, Summer
Gilloteau, Isabelle
Blauvelt, Andrew
Lebwohl, Mark
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB274 - AB274

← 1 2 3 4 5 →